MA38397A1 - Agglomérats inhalables de particules de support poreuses et médicament micronisé - Google Patents
Agglomérats inhalables de particules de support poreuses et médicament microniséInfo
- Publication number
- MA38397A1 MA38397A1 MA38397A MA38397A MA38397A1 MA 38397 A1 MA38397 A1 MA 38397A1 MA 38397 A MA38397 A MA 38397A MA 38397 A MA38397 A MA 38397A MA 38397 A1 MA38397 A1 MA 38397A1
- Authority
- MA
- Morocco
- Prior art keywords
- inhalable
- agglomerates
- porous carrier
- carrier particles
- particles
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4704—2-Quinolinones, e.g. carbostyril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1611—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Pulmonology (AREA)
- Inorganic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Otolaryngology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La présente invention concerne une composition pharmaceutique destinée à être administrée par voie pulmonaire qui se présente sous la forme de poudre sèche contenant des particules de support poreuses et des particules de principe actif. Les particules de support poreuses et les particules de principe actif forment un mélange ordonné d'agglomérats inhalables utiles pour traiter des maladies pulmonaires. Les particules de principe actif peuvent comprendre un, deux, trois ingrédients actifs ou plus. L'invention concerne également un procédé de séchage par pulvérisation destiné à la préparation des agglomérats inhalables.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361784842P | 2013-03-14 | 2013-03-14 | |
PCT/IB2014/059739 WO2014141135A1 (fr) | 2013-03-14 | 2014-03-13 | Agglomérats inhalables de particules de support poreuses et médicament micronisé |
Publications (1)
Publication Number | Publication Date |
---|---|
MA38397A1 true MA38397A1 (fr) | 2018-01-31 |
Family
ID=50478894
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA38397A MA38397A1 (fr) | 2013-03-14 | 2014-03-13 | Agglomérats inhalables de particules de support poreuses et médicament micronisé |
Country Status (22)
Country | Link |
---|---|
US (2) | US9452139B2 (fr) |
EP (1) | EP2968570A1 (fr) |
JP (1) | JP6374414B2 (fr) |
KR (1) | KR20150129716A (fr) |
CN (1) | CN105188757B (fr) |
AU (2) | AU2014229265A1 (fr) |
BR (1) | BR112015021814A2 (fr) |
CA (1) | CA2905615A1 (fr) |
CL (1) | CL2015002632A1 (fr) |
EA (1) | EA201591729A1 (fr) |
GT (1) | GT201500295A (fr) |
HK (1) | HK1212616A1 (fr) |
IL (1) | IL240963A (fr) |
MA (1) | MA38397A1 (fr) |
MX (1) | MX2015012814A (fr) |
PE (1) | PE20151655A1 (fr) |
PH (1) | PH12015501882A1 (fr) |
SA (1) | SA515361055B1 (fr) |
SG (1) | SG11201506397QA (fr) |
TN (1) | TN2015000395A1 (fr) |
WO (1) | WO2014141135A1 (fr) |
ZA (1) | ZA201505768B (fr) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL3219705T3 (pl) | 2005-12-28 | 2020-08-10 | Vertex Pharmaceuticals Incorporated | Kompozycje farmaceutyczne amorficznych postaci n-[2,4-bis(1,1-dimetyloetylo)-5-hydroksyfenylo]-1,4-dihydro-4-oksochinolino-3-karboksyamidu |
US8563573B2 (en) | 2007-11-02 | 2013-10-22 | Vertex Pharmaceuticals Incorporated | Azaindole derivatives as CFTR modulators |
TWI433674B (zh) | 2006-12-28 | 2014-04-11 | Infinity Discovery Inc | 環杷明(cyclopamine)類似物類 |
US8802868B2 (en) | 2010-03-25 | 2014-08-12 | Vertex Pharmaceuticals Incorporated | Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide |
MX353408B (es) | 2010-04-22 | 2018-01-11 | Vertex Pharma | Proceso para producir compuestos de cicloalquilcarboxamido-indol. |
JP2016506947A (ja) * | 2013-01-31 | 2016-03-07 | プロソニックス リミテッド | 吸入療法において使用するのに適する多成分結晶粒子を含む医薬組成物 |
US9452139B2 (en) * | 2013-03-14 | 2016-09-27 | Novartis Ag | Respirable agglomerates of porous carrier particles and micronized drug |
AU2015237857B2 (en) * | 2014-03-27 | 2017-08-10 | Novartis Ag | Spray-dried solid-in-oil-in-water dispersions for inhalation of active pharmaceutical ingredients |
WO2015160787A1 (fr) | 2014-04-15 | 2015-10-22 | Vertex Pharmaceuticals Incorporated | Compositions pharmaceutiques destinées au traitement des maladies liées au régulateur de la conductance transmembranaire de la mucoviscidose |
CN107250113B (zh) | 2014-10-07 | 2019-03-29 | 弗特克斯药品有限公司 | 囊性纤维化跨膜传导调节蛋白的调节剂的共晶 |
WO2016142708A2 (fr) * | 2015-03-10 | 2016-09-15 | Cipla Limited | Composition pharmaceutique |
US10423736B2 (en) * | 2015-08-28 | 2019-09-24 | University Of British Columbia | Methods and systems for simulating hydrodynamics in gas-solid fluidized beds |
EP3335699A1 (fr) | 2016-12-15 | 2018-06-20 | H e x a l Aktiengesellschaft | Formulation de sélexipag dans un système liquisolide |
CN106943350A (zh) * | 2017-03-14 | 2017-07-14 | 上海现代药物制剂工程研究中心有限公司 | 含毒蕈碱受体拮抗剂和β2受体激动剂的气雾剂及制备方法 |
WO2019060595A1 (fr) * | 2017-09-20 | 2019-03-28 | Teva Branded Pharmaceutical Products R&D, Inc. | Médicament inhalable en poudre sèche comprenant du glycopyrronium |
US20200324064A1 (en) * | 2019-04-10 | 2020-10-15 | Cai Gu Huang | Inhalation Device for Administering Powdered Pharmaceutical Composition |
US20200375945A1 (en) * | 2019-06-03 | 2020-12-03 | Cai Gu Huang | Inhalable formulation of a solution containing indacaterol maleate and glycopyrronium bromide |
EP4013245A1 (fr) * | 2019-08-15 | 2022-06-22 | Abbott Laboratories | Procédé de fabrication de poudre nutritionnelle utilisant la micronisation, et composition de poudre |
CN115916173A (zh) * | 2020-04-13 | 2023-04-04 | 巴塞尔大学医院 | Lsd剂量鉴定 |
CN114344285B (zh) * | 2020-10-14 | 2023-11-14 | 江苏恒瑞医药股份有限公司 | 改良的可吸入团聚物 |
CN116546980A (zh) * | 2020-12-11 | 2023-08-04 | 江苏恒瑞医药股份有限公司 | 用于肺部递送的药物组合物 |
CN113318097A (zh) * | 2021-04-29 | 2021-08-31 | 珠海瑞思普利医药科技有限公司 | 一种抗特发性肺纤维化的粉雾剂及制备方法 |
Family Cites Families (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2956062A (en) | 1959-02-26 | 1960-10-11 | Robins Co Inc A H | Esters of amino alcohols |
IT1016489B (it) | 1974-03-18 | 1977-05-30 | Isf Spa | Inalatore |
ATE8790T1 (de) | 1981-02-02 | 1984-08-15 | Schering Corporation | Aromatische heterocyclische steroidester, verfahren zu ihrer herstellung und pharmazeutische zusammensetzungen, die sie enthalten. |
SE448277B (sv) | 1985-04-12 | 1987-02-09 | Draco Ab | Indikeringsanordning vid en doseringsanordning for lekemedel |
US6536427B2 (en) | 1990-03-02 | 2003-03-25 | Glaxo Group Limited | Inhalation device |
AR245596A1 (es) | 1991-06-26 | 1994-02-28 | Schering Corp | Dispositivo inhalador de medicamentos en polvo |
WO1994014492A2 (fr) | 1992-12-18 | 1994-07-07 | Schering Corporation | Inhalateur pour medicaments en poudre |
US6794357B1 (en) * | 1993-06-24 | 2004-09-21 | Astrazeneca Ab | Compositions for inhalation |
US5837699A (en) | 1994-01-27 | 1998-11-17 | Schering Corporation | Use of mometasone furoate for treating upper airway passage diseases |
BR9508964A (pt) | 1994-09-21 | 1998-06-02 | Inhale Therapeutic Syst | Processo e aparelho de aerossolização conjunto de tubo de alimentação e receptáculo para contenção de um medicamento pulverizado |
AP9801285A0 (en) | 1996-01-03 | 1998-09-30 | Glaxo Group Ltd | Inhalation device. |
ATE216903T1 (de) | 1996-02-21 | 2002-05-15 | Schering Corp | Inhalator für pulverartiges medikament |
US6613795B2 (en) | 1996-11-11 | 2003-09-02 | Christian Noe | Enantiomerically pure basic arylcycloalkylhydroxycarboxylic esters, processes for their preparation and their use in medicaments |
EP0937041B1 (fr) | 1996-11-11 | 2003-04-23 | Christian R. Noe | Utilisation d'un sel pharmaceutiquement acceptable de (3R,2'R)-3-[(cyclopentyl-hydroxyphenylacetyl)oxy]1,1-dimethyl-pyrrolidimium pour la préparation d'un médicament |
US6010935A (en) | 1997-08-21 | 2000-01-04 | Micron Technology, Inc. | Self aligned contacts |
US6565885B1 (en) | 1997-09-29 | 2003-05-20 | Inhale Therapeutic Systems, Inc. | Methods of spray drying pharmaceutical compositions |
UA73924C2 (en) | 1998-10-09 | 2005-10-17 | Nektar Therapeutics | Device for delivering active agent formulation to lungs of human patient |
US20070212422A1 (en) | 1999-11-10 | 2007-09-13 | Manfred Keller | Dry powder for inhalation |
CA2347856C (fr) | 1998-11-13 | 2009-02-17 | Jago Research Ag | Poudre seche pour inhalation |
GB9913083D0 (en) | 1999-06-04 | 1999-08-04 | Novartis Ag | Organic compounds |
ES2265944T3 (es) | 1999-05-28 | 2007-03-01 | Nektar Therapeutics | Aparato y procedimiento para aerosolizar una composicion farmaceutica en polvo. |
US6679256B2 (en) | 1999-12-17 | 2004-01-20 | Nektar Therapeutics | Systems and methods for extracting powders from receptacles |
US7069929B2 (en) | 2000-02-01 | 2006-07-04 | Quadrant Technologies Limited | Dry powder inhaler |
US7871598B1 (en) | 2000-05-10 | 2011-01-18 | Novartis Ag | Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use |
WO2001085136A2 (fr) | 2000-05-10 | 2001-11-15 | Alliance Pharmaceutical Corporation | Poudres a base de phospholipides permettant de distribuer un medicament |
GB0201677D0 (en) | 2002-01-25 | 2002-03-13 | Glaxo Group Ltd | Medicament dispenser |
WO2004054556A1 (fr) | 2002-12-13 | 2004-07-01 | Adagit | Particules pharmaceutiques poreuses |
MXPA05010842A (es) | 2003-04-09 | 2006-03-30 | Nektar Therapeutics | Aparato de nebulizacion con protector de entrada de aire. |
GB0317374D0 (en) | 2003-07-24 | 2003-08-27 | Glaxo Group Ltd | Medicament dispenser |
GB2407042B (en) | 2003-10-17 | 2007-10-24 | Vectura Ltd | Inhaler |
AU2005216061B2 (en) | 2004-02-24 | 2010-05-27 | Microdose Therapeutx, Inc. | Synthetic jet based medicament delivery method and apparatus |
GB0410712D0 (en) | 2004-05-13 | 2004-06-16 | Novartis Ag | Organic compounds |
GB0413960D0 (en) | 2004-06-22 | 2004-07-28 | Novartis Ag | Organic compounds |
ITMI20051999A1 (it) | 2005-10-21 | 2007-04-22 | Eratech S R L | Formulazioni inalatorie di farmaci in fora di polvere secca per somministrazione come tale o con nebulizzatore e dotate di elevata erogabilita' respirabilita' e stabilita' |
GB0613161D0 (en) * | 2006-06-30 | 2006-08-09 | Novartis Ag | Organic Compounds |
SI2044025T1 (sl) | 2006-06-30 | 2013-01-31 | Novartis Ag | Kinolinonski derivati in njihovi farmacevtski sestavki |
JP2010508069A (ja) | 2006-10-25 | 2010-03-18 | ノバルティス アーゲー | パウダー分散装置、その装置の製造方法および使用方法、その装置および他の装置に使用される構成要素 |
WO2009140587A1 (fr) | 2008-05-15 | 2009-11-19 | Novartis Ag | Administration pulmonaire d'une fluoroquinolone |
CA2758100C (fr) | 2009-04-09 | 2017-08-29 | Novartis Ag | Procede de preparation de sels de pyrrolidinium |
US8815258B2 (en) * | 2009-05-29 | 2014-08-26 | Pearl Therapeutics, Inc. | Compositions, methods and systems for respiratory delivery of two or more active agents |
EP2552424B1 (fr) | 2010-04-01 | 2018-05-09 | Chiesi Farmaceutici S.p.A. | Procédé de préparation de particules d'excipient pour poudres sèches à inhaler |
JOP20120023B1 (ar) * | 2011-02-04 | 2022-03-14 | Novartis Ag | صياغات مساحيق جافة من جسيمات تحتوي على واحد أو اثنين من المواد الفعالة لعلاج امراض ممرات الهواء الانسدادية او الالتهابية |
US9452139B2 (en) * | 2013-03-14 | 2016-09-27 | Novartis Ag | Respirable agglomerates of porous carrier particles and micronized drug |
-
2014
- 2014-03-10 US US14/202,262 patent/US9452139B2/en active Active
- 2014-03-13 BR BR112015021814A patent/BR112015021814A2/pt active Search and Examination
- 2014-03-13 EP EP14716933.8A patent/EP2968570A1/fr not_active Withdrawn
- 2014-03-13 CA CA2905615A patent/CA2905615A1/fr not_active Abandoned
- 2014-03-13 EA EA201591729A patent/EA201591729A1/ru unknown
- 2014-03-13 MA MA38397A patent/MA38397A1/fr unknown
- 2014-03-13 JP JP2015562509A patent/JP6374414B2/ja active Active
- 2014-03-13 AU AU2014229265A patent/AU2014229265A1/en not_active Abandoned
- 2014-03-13 CN CN201480015125.XA patent/CN105188757B/zh active Active
- 2014-03-13 KR KR1020157024586A patent/KR20150129716A/ko not_active Application Discontinuation
- 2014-03-13 MX MX2015012814A patent/MX2015012814A/es unknown
- 2014-03-13 WO PCT/IB2014/059739 patent/WO2014141135A1/fr active Application Filing
- 2014-03-13 PE PE2015001910A patent/PE20151655A1/es not_active Application Discontinuation
- 2014-03-13 SG SG11201506397QA patent/SG11201506397QA/en unknown
-
2015
- 2015-08-11 ZA ZA2015/05768A patent/ZA201505768B/en unknown
- 2015-08-26 PH PH12015501882A patent/PH12015501882A1/en unknown
- 2015-08-31 IL IL240963A patent/IL240963A/en active IP Right Grant
- 2015-09-04 TN TN2015000395A patent/TN2015000395A1/en unknown
- 2015-09-11 CL CL2015002632A patent/CL2015002632A1/es unknown
- 2015-09-13 SA SA515361055A patent/SA515361055B1/ar unknown
- 2015-09-14 GT GT201500295A patent/GT201500295A/es unknown
-
2016
- 2016-01-20 HK HK16100598.8A patent/HK1212616A1/zh unknown
- 2016-08-17 US US15/238,842 patent/US9744178B2/en active Active
-
2017
- 2017-05-16 AU AU2017203258A patent/AU2017203258B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
AU2017203258A1 (en) | 2017-06-08 |
MX2015012814A (es) | 2016-02-03 |
IL240963A (en) | 2017-05-29 |
TN2015000395A1 (en) | 2017-01-03 |
BR112015021814A2 (pt) | 2017-07-18 |
US20140302147A1 (en) | 2014-10-09 |
AU2014229265A1 (en) | 2015-09-03 |
JP6374414B2 (ja) | 2018-08-15 |
HK1212616A1 (zh) | 2016-06-17 |
AU2017203258B2 (en) | 2019-06-20 |
WO2014141135A1 (fr) | 2014-09-18 |
PH12015501882A1 (en) | 2015-12-07 |
IL240963A0 (en) | 2015-11-30 |
CN105188757B (zh) | 2019-04-30 |
PE20151655A1 (es) | 2015-11-26 |
CL2015002632A1 (es) | 2016-03-28 |
SG11201506397QA (en) | 2015-09-29 |
US20160354388A1 (en) | 2016-12-08 |
SA515361055B1 (ar) | 2016-11-13 |
ZA201505768B (en) | 2017-03-29 |
KR20150129716A (ko) | 2015-11-20 |
GT201500295A (es) | 2017-09-28 |
US9744178B2 (en) | 2017-08-29 |
CA2905615A1 (fr) | 2014-09-18 |
JP2016512494A (ja) | 2016-04-28 |
CN105188757A (zh) | 2015-12-23 |
EA201591729A1 (ru) | 2016-05-31 |
EP2968570A1 (fr) | 2016-01-20 |
US9452139B2 (en) | 2016-09-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA38397A1 (fr) | Agglomérats inhalables de particules de support poreuses et médicament micronisé | |
JOP20210017A1 (ar) | مثبطات جسيم التهابي nlrp3 | |
DE60129573D1 (de) | Verfahren zur sprühtrocknung von zusammensetzungen enthaltend fenofibrat | |
EA201390049A1 (ru) | Сухой порошковый препарат, содержащий ингибитор фосфодиэстеразы | |
ES2643693T3 (es) | Composición farmacéutica de rosuvastatina cálcica | |
CL2022000033A1 (es) | Composición farmacéutica para suministro nasal | |
ATE470443T1 (de) | Indol-1-yl-essigsäurederivate | |
BRPI0508170A (pt) | formulações farmacêuticas para inaladores de pó seco, que compreendem um ingrediente ativo de potência de baixa dosagem | |
MX344787B (es) | Composiciones que contienen berberina o analogos de la misma para tratar rosacea o trastornos de la piel relacionados con enrojecimiento de la cara. | |
MA34326B1 (fr) | Formulation de poudre sèche comprenant un médicament antimuscarinique | |
DE602008003404D1 (de) | 5,6,7,8-tetrahydropteridin-derivate als hsp90-hemmer | |
MA43876B1 (fr) | Compositions pharmaceutiques et leur utilisations contre les maladies de surcharge lysosomale | |
EA201401309A1 (ru) | Фармацевтическая композиция для ингаляции, содержащая аклидиний, и её применение | |
BRPI0620629B8 (pt) | composição farmacêutica, processo para preparar uma composição farmacêutica e seu uso | |
MY191712A (en) | Composition comprising at least one dry powder obtained by spray drying to increase the stability of the formulation | |
BR112015020443A2 (pt) | desamorfização de formulações secadas por atomização via mistura por atomização | |
EA200500387A1 (ru) | Композиции для ингаляции с высоким содержанием лекарственных веществ | |
MA34130B1 (fr) | Formulations pharmaceutiques solides de ramipril et de bésylate d'amlodipine et leur préparation | |
EA026665B1 (ru) | Твердые формы препаратов иматиниба, ресуспензируемые непосредственно перед применением | |
EA202092922A1 (ru) | Фармацевтический состав с улучшенной растворимостью и биологической доступностью | |
EA201792159A1 (ru) | Способ получения сухих порошкообразных смесей | |
MA35698B1 (fr) | Nouvelle composition du 3,4-diaminopyridin pour le traitement de la fatigabilité musculaire associée à des troubles neurovégétatifs. | |
EA202091127A1 (ru) | Фармацевтические композиции, включающие сафинамид | |
EA202092944A1 (ru) | Применение пероральных распадающихся таблеток рилузола для лечения заболеваний | |
RU2150273C1 (ru) | Антигипоксическое и актопротекторное средство |